An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

NCT00417118 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

365

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Anxiety

Interventions

DRUG: Saredutant
DRUG: Escitalopram
DRUG: Placebo

Sponsor

Sanofi